Skip to main content
48°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
25.65
+0.52 (+2.07%)
Official Closing Price
Updated: 7:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Nasdaq Hits Record High Ahead Of Big Tech Earnings: Fear Index Remains In 'Greed' Zone
October 30, 2024
Via
Benzinga
Why Pfizer Stock Tumbled on Tuesday
October 29, 2024
The specter of an activist investor looms over the company.
Via
The Motley Fool
Pfizer (PFE) Q3 2024 Earnings Call Transcript
October 29, 2024
PFE earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biotech Momentum Trades For The Q4 Rally
October 29, 2024
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading.
Via
Talk Markets
Tech Stocks Rise Ahead Of Key Earnings, Gold Smashes Records, Bitcoin Nears All-Time Highs: What's Driving Markets Tuesday?
October 29, 2024
Wall Street took a breather on Tuesday, with most major indices treading water, while tech stocks saw gains as investors braced for earnings reports from mega-cap companies.
Via
Benzinga
Pfizer Earnings Top Q3 Views; Pharma Giant Guides Higher
October 29, 2024
The drug giant comfortably beat estimates and raised full-year guidance.
Via
Investor's Business Daily
Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views
October 29, 2024
Via
Benzinga
Pfizer Inc.’s Strong Q3 Performance: Beats Expectations With $1.06 EPS
October 29, 2024
Pfizer Inc. reported stellar third-quarter financial results, with revenues surging to $17.7 billion.
Via
Talk Markets
Pfizer Q3 Earnings: Revenue And Profit Beat On Heightened Demand For Paxlovid, Expects $10 Billion In 2024 Revenue From COVID Products
October 29, 2024
Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, Comirnaty, and Seagen contributions.
Via
Benzinga
Exposures
COVID-19
US Stocks Likely To Open Weaker As Investors Eye Alphabet, AMD And Pfizer Earnings: Expert Says Won't Be 'Surprised' If Earnings Exceed Wall Street Expectations
October 29, 2024
U.S. stocks could see a weak opening on Tuesday after the averages registered a mixed last week.
Via
Benzinga
Key Takeaways From Pfizer Analyst Ratings
October 23, 2024
Via
Benzinga
A Closer Look at Pfizer's Options Market Dynamics
October 23, 2024
Via
Benzinga
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
October 29, 2024
From
Pfizer Inc.
Via
Business Wire
Dow Surges Over 250 Points Ahead Of Alphabet, Pfizer Earnings: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
October 29, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pfizer, Alphabet And 3 Stocks To Watch Heading Into Tuesday
October 29, 2024
Via
Benzinga
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
October 28, 2024
Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support.
Via
Benzinga
What Lies In Store For Healthcare ETFs In Q3 Earnings?
October 27, 2024
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited.
Via
Talk Markets
Topics
ETFs
These 7 Blunt Words Just Opened a Can of Worms For Pfizer's Stock
October 27, 2024
The company's problems are no longer deniable.
Via
The Motley Fool
3 Magnificent S&P 500 Dividend Stocks Down 43%, 20%, and 53% to Buy and Hold Forever
October 26, 2024
The market is overlooking the bigger picture for these three names. That means opportunity for you.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
3 Spooky Signs That You're About to Lose Your Money on a Healthcare Stock Investment
October 26, 2024
Knowing these will help you avoid making suboptimal investing decisions.
Via
The Motley Fool
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
October 25, 2024
Pfizer shares fell 0.8% to close at $28.64 during Thursday's session. Live Nation Entertainment shares gained 1.5% to close at $116.45.
Via
Benzinga
Got $1,000? 2 Healthcare Stocks to Buy and Hold Forever.
October 25, 2024
These two stocks have moved in different directions this year, but that shouldn't mean much to long-term investors.
Via
The Motley Fool
3 Sweet Dividend Stocks to Treat Your Portfolio With This Halloween
October 25, 2024
There are more reasons to buy these stocks besides their high payouts.
Via
The Motley Fool
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
October 24, 2024
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for millions at risk of serious disease.
Via
Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
October 24, 2024
The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines.
Via
Benzinga
5 High-Yield Dividend Stocks to Buy Without Hesitation
October 24, 2024
These five dividend powerhouses offer yields above 4%.
Via
The Motley Fool
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.
Via
Benzinga
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
October 23, 2024
From
Pfizer Inc.
Via
Business Wire
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
October 23, 2024
Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals to safeguard infants from birth.
Via
Benzinga
Exposures
Product Safety
The Best Pharmaceutical Stock to Invest $1,000 in Right Now
October 23, 2024
Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.